Interim Analysis Shows Abiraterone Acetate Significantly Improves Radiographic Progression-Free Survival in Chemo-Naïve Metastatic Castration-Resistant Prostate Cancer
Interim Analysis Shows Abiraterone Acetate Significantly Improves Radiographic Progression-Free Surv
Patients with asymptomatic and mildly symptomatic chemotherapy-naïve metastatic castration-resistant prostate cancer had significantly improved radiographic progression-free survival (rPFS) and showed a strong trend for increased overall survival (OS) following treatment with abiraterone acetate plus prednisone compared with prednisone alone, according to second interim analysis results of a study presented at the 2012 Annual Meeting of the American Society of Clinical Oncology.INTENDED AUDIENCE:
Physicians, nurse practitioners, physician assistants, nurses, and other healthcare providers who manage patients with prostate cancer.Activity Objectives:
After participating in this educational activity, participants should be better able to:
- Analyze the impact of abiraterone acetate plus prednisone on pain palliation, delayed pain progression, and delayed time to skeletal-related events.
- Integrate new approaches into the management of adults with metastatic castration-resistant prostate cancer.
Click Next to begin the activity.